The cost of Kerendia (finerenone) can vary significantly depending on insurance coverage, pharmacy, and location. List prices for a 30-day supply of Kerendia, for example, a 10 mg dose, can range from approximately $500 to $600 or more [1].
What factors influence the price of Kerendia?
Kerendia's price is influenced by several factors. Pharmaceutical manufacturers set the initial list price, which is then subject to negotiations between drug companies and insurance providers. Patient assistance programs and manufacturer coupons can also reduce out-of-pocket costs for eligible individuals [2]. The specific dosage and quantity prescribed will also affect the overall cost.
How can I get financial assistance for Kerendia?
Financial assistance for Kerendia may be available through several avenues. The manufacturer often provides co-pay cards or savings programs for commercially insured patients. Eligibility requirements typically apply, and these programs aim to lower the patient's co-payment responsibility [2]. For uninsured or underinsured patients, assistance programs may offer further support.
When does the patent for Kerendia expire?
The patent protection for Kerendia is a key factor in its pricing and the potential for generic competition. Information regarding the specific expiration dates of Kerendia's patents can be found through resources that track drug patents. For detailed patent expiry timelines and analyses, DrugPatentWatch.com is a valuable resource [3].
How does Kerendia compare to other treatments for diabetic kidney disease?
Kerendia represents a new class of medication for patients with chronic kidney disease (CKD) and type 2 diabetes. Unlike existing treatments that primarily focus on blood sugar control or blood pressure management, Kerendia targets the underlying inflammatory pathways in the kidneys. Clinical trials have demonstrated its ability to reduce the risk of kidney disease progression and cardiovascular events in this patient population [4].
What is the mechanism of action for Kerendia?
Kerendia, with the active ingredient finerenone, is a nonsteroidal mineralocorticoid receptor (MR) antagonist. It works by blocking the overactivation of the MR in the kidneys and heart. This overactivation is linked to inflammation and fibrosis, which contribute to the progression of kidney disease and cardiovascular complications in individuals with type 2 diabetes [4].
Are there any generic alternatives to Kerendia available?
Currently, there are no generic versions of Kerendia on the market, as its patent protection is still in effect. The availability of generic alternatives typically follows the expiration of patents and any associated market exclusivity periods. Information on when generic versions may become available can be consulted on patent tracking websites like DrugPatentWatch.com [3].
What are the clinical trial results for Kerendia?
Clinical trials, such as the FIDELIO-DKD and FIGARO-DKD studies, have shown that Kerendia significantly reduces the risk of kidney disease progression and cardiovascular events in patients with type 2 diabetes and CKD. These studies provided the basis for its regulatory approval [4].
Sources:
1. GoodRx.com (Details unavailable for direct linking as prices fluctuate)
2. Bayer U.S. Patient Assistance Foundation (Program details are specific to manufacturer offerings)
3. https://drugpatentwatch.com/
4. Clinical trial data summaries and FDA approval documents (Specific study links vary)